Alzheimer's disease & dementia

Alzheimer's and aducanumab: Unjust profits and false hopes

The U.S. Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's disease raises at least three major ethical issues that need to be addressed, states a new article in the ...

Health

Speaking up to give voice to the severely disabled

The question of who speaks for patients with traumatic brain injuries when considering medical decisions is the subject of a commentary in the American Journal of Bioethics Neuroscience by Marie-Christine Nizzi, a research ...

page 1 from 2